Visterra Strikes Deal With Pfizer, Presents Strong Data For Flu Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
The start-up supplied few details about its arrangement with its Big Pharma partner, but receives cash as it prepares to take a promising influenza therapy into the clinic.
You may also be interested in...
Deals Of The Week: Merck/Simcere, Pfizer/Hisun, MedImmune/WuXi
The growing importance of emerging markets will be a primary discussion point Sept. 17-19 at Elsevier’s Pharmaceutical Strategic Alliances conference in New York
United Therapeutics Scores $45 Million To Develop Novel Virology Treatments
United Therapeutics Corp. gets a $45 million tranched grant from the U.S. National Institute of Allergy and Infectious Disease to develop broad-spectrum compounds against influenza and Dengue.
Craig Venter Wants To Extend Your Life (And Own Your Data)
The onetime Celera CEO says his new attempt to centralize biological information into a massive database could lead to breakthroughs that extend the human life span. Behind that bold goal is a more mundane data-licensing strategy that, although not splashy, could still improve medicine.